LONDON, December 9 /PRNewswire/ -- The Parkinson's disease therapeutics market in 2008 amounted to over US$1 billion in the European Union (EU), which includes total sales of carbidopa/levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors and anticholinergics used for disease symptom relief. With the introduction of newer dopamine agonists as well as fresh recommendations and treatment guidelines that call for using dopamine agonists as first-line therapy, the market is experiencing a shift away from the use of carbidopa/levodopa.
(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)
New analysis from Frost Sullivan (http://www.pharma.frost.com), European Markets for Parkinson's Disease Therapeutics, finds that the market earned revenues of over US$1.28 billion in 2008 and estimates this to reach US$2.28 billion in 2015.
Although prescriptions for Sinemet and Sinemet controlled release (CR) continue to be written to a large extent, dopamine agonists prescriptions are increasing as well, says Frost Sullivan Programme manager Paljit Sohal. Other drugs account for a relatively small portion of the total prescriptions, while some, such as the catechol-o-methyltransferase (COMT) inhibitors are directly linked with Sinemet prescriptions.
The introduction of Mirapex and Requip has been largely responsible for driving the market over the recent period. The increased use of these medications is spurred by the recent announcements from key physician groups recommending their use in early-stage Parkinson's disease and calling for delay in the use of carbidopa/levodopa due to concerns over the development of clinically relevant dyskinesias.
However, there are considerable chances for physicians to misdiagnose Parkinson's disease. The number of cases that go undiagnosed or misdiagnosed each year range from approximately 20.0 per cent to 40.0 per cent of the total cases. In most cases, the disease is not diagnosed until 80 per cent of the dopamine-producing neurotransmitters are depleted. Earlier diagnosis and treatment has the potential to greatly improve prognosis.
An estimated one million patients are afflicted with the disease and as many as 4,00,000 are improperly diagnosed or under-diagnosed, explains Ms. Sohal. Recognising the early signs of the disease and making a referral to a neurologist represent the potential for the disease to go undiagnosed.
Biomarkers and imaging techniques are likely to improve the diagnosis of the condition at a much earlier stage and hence, their development should be supported. High-risk individuals must be identified prior to clinical onset of the disease and disease progression along with response to various therapies should be monitored.
Market participants should collaborate with neurologists and physicians to improve the rate and the process of diagnosis, concludes Ms. Sohal. This will expand the target population and thereby, market revenues.
If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, then send an e-mail to Katja Feick, Corporate Communications, at katja.feick@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, a brochure will be sent to you by e-mail.
European Markets for Parkinson's Disease Therapeutics is part of the Pharmaceuticals Biotechnology Growth Partnership Services programme, which also includes research in the following markets: European Biosimilars Market Outlook, Eastern Drug Delivery Markets - Opportunity Analysis, and European Lung Cancer Therapeutics Markets. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.
About Frost Sullivan
Frost Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.
European Markets for Parkinson's Disease Therapeutics (M32D)
Contact: Katja Feick Corporate Communications - Europe P: +49-(0)-69-7703343 E: katja.feick@frost.com
SOURCE: Frost SOURCE: Sullivan
CONTACT: Katja Feick, Corporate Communications - Europe, Frost Sullivan,+49-(0)-69-7703343, katja.feick@frost.com
Comments